Celltrion Pharm Inc (068760.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7068760008

Price
40,000.00 KRW
Market cap
1.77 tn KRW
P/E (2025)
45.72
P/S (2025)
3.30
Dividend yield
0.50 %
Net margin
7.22 %
Return on equity (ROE)
8.89 %
Return on assets (ROA)
5.10 %

Celltrion Pharm Inc financials

Fiscal year20242025
Revenue477.84 bn KRW536.40 bn KRW
Gross profit122.01 bn KRW163.78 bn KRW
Operating income37.22 bn KRW56.09 bn KRW
EBIT37.26 bn KRW56.38 bn KRW
Net income21.97 bn KRW38.75 bn KRW
Diluted EPS – continuing operations505.39 KRW874.86 KRW

Full history since 2006, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Celltrion Pharm Inc

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea. Celltrion Pharm, Inc. (KOSDAQ:A068760) operates as a subsidiary of Celltrion, Inc.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.